Studies have focused on the use of monoclonal antibodies (mAbs) that bind to PD-1 or PD-L1, preventing the PD-1/PD-L1 interaction, resulting in the restoration of the anti-cancer immune response. The gene discussed is CD274; the disease is cancer.